Zentalis Pharmaceuticals (ZNTL) Change in Acquisitions & Divestments (2020 - 2026)

Zentalis Pharmaceuticals' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $60.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments changed 0.0% year-over-year to $60.0 million in Q1 2026; TTM through Mar 2026 was $250.0 million, a 1047.89% increase from a year earlier, with the FY2025 full-year figure at $250.0 million, up 646.74% from the prior year.
• Change in Acquisitions & Divestments steadied at $60.0 million in Q1 2026 per ZNTL's latest filing, from $60.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $198.5 million in Q2 2023 and bottomed at -$307.3 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $60.0 million (2025), against an average of $49.9 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 251.25% in 2023 and tumbled 407.25% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at -$307.3 million in 2022, then soared by 117.61% to $54.1 million in 2023, then tumbled by 407.25% to -$166.2 million in 2024, then surged by 136.1% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
• Per Business Quant, the three latest ZNTL Change in Acquisitions & Divestments figures stand at $60.0 million (Q1 2026), $60.0 million (Q4 2025), and $60.0 million (Q3 2025).